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Ligand-filled porcine estradiol receptor was adsorbed to heparin-Sepharose, from which a 26 kDa fragment was released by papain. Its mass was 
reduced to a 17 kDa fragment by trypsin. The sedimentation velocities of both estradiol binding fragments increased after reaction with the MAB 
13H2. The same antibody identified the denatured fragments on Western blots. The N-terminal 21 amino acid sequence was obtained from the 
17 kDa peptide which corresponds to amino acids 303- 323 of the human receptor with four amino acids exchanged. This indicates that the ligand 
binding site resides in the N-terminal 17 kDa portion of domain E. 
Estradiol receptor; Steroid hormone receptor; Domain E; Estrogen 
1. INTRODUCTION 2. MATERIALS AND METHODS 
The steroid binding domain E of the estradiol recep- 
tor was deduced from deletion experiments [l]. It ex- 
tends from amino acids 302 to 552 of the human se- 
quence [l] and is also involved in receptor dimerisation 
[2], interaction with heat-shock proteins [3], transcrip- 
tional activation [4] and may contain the proposed au- 
toproteolytic center [5]. Detailed assignments of the var- 
ious properties have been pursued by functional analy- 
ses of the products of large deletion mutants [1,4] as well 
as of point mutations [2,6,7]. The search for an estradiol 
binding site in the large domain can also proceed by 
analysing the fragments resulting from limited diges- 
tions of either unfilled or ligand-filled wild type receptor 
[8]. The hormone-labelled receptor is of greater promise 
than the unlabelled one, because the ligand-induced 
conformational change leaves fewer sites accessible to 
proteolytic attack [9]. Their number can be further re- 
duced by attaching ligand-filled intact receptor to an 
insoluble matrix such as heparin-Sepharose, from which 
a 32 kDa peptide spanning most of domain E [lo] is 
released by traces of endogenous plasmin [l 11. This 
procedure leaves some lO-20% of the initially adsorbed 
receptor bound to the matrix. The recovery of the bal- 
ance of estradiol-filled receptor as a 26 kDa fragment 
by papain, its digestion to 17 kDa by trypsin and the 
characterization of both peptides are described in this 
report. 
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[(6,7)-‘H]Estradiol, spec. act. 2.22 TBq/mmol, obtained from NEN 
(Dreieich), was diluted with unlabelled steroid to 75-222 GBq/mmol. 
Trypsin (TPCK treated) and papain were from Sigma. ProBlott mem- 
branes and all sequencer reagents were from Applied Biosystems. 
2.1. Monoclonal and polyclonal antibodies 
The antibodies are directed against a 32 kDa estradiol receptor 
fragment [lo] containing the whole of domain E. The monoclonal 
antibody 13H2 [12,13] was purified from hybridoma supematant by 
protein A-Sepharose chromatography. The IgG, fraction of the poly- 
clonal anti-estradiol receptor antiserum #402 [10,14,15] was purified 
by protein G-Sepharose and Mono-Q chromatography. 
2.2. Preparation of receptor fragments 
The papain receptor fragment was obtained by an extension of the 
method described in [10,16]. All operations were carried out at 4°C 
in the presence of an excess of estradiol. Briefly, the procedure in- 
cluded the adsorption of ligand-filled receptor from porcine uterine 
extracts (approx. 20 1) to heparin-Sepharose (1 1) in batch operation 
and washes of the adsorbent, filled into a 10 x 13 cm column, with 0.2 
M KC1 buffered with 0.01 M glycylglycine/piperazine-HCl (Smith and 
Smith buffer, S&S) to pH 7.4, followed by 0.3 M KC1 in the same 
buffer containing 0.05 M dithiothreitol. The column was then short- 
circuited through a reservoir and recycled for 24 h. After the elution 
of the first recycling fluid containing the 32 kDa fragment [lo], the 
adsorbent was washed with 0.3 M KCl, 0.01 M S&S, pH 7.4, until 
OD,,, reached baseline. The column was next fed with digestion buffer 
(1 1 of 0.3 M KCl, 0.01 M S&S, pH 6.8, 0.002 M DTT containing 5 
mg papain) and was again short-circuited for 24 h at a pumping rate 
of 150 ml/h. The recirculating fluid was then displaced from the col- 
umn by buffer, and solid (NH&SO, was added to the eluate to 40% 
saturation. The precipitated material was collected by centrifugation, 
dissolved in 70 ml 0.3 M KCl, 0.01 M S&S, pH 8, dialysed against he 
same buffer, and the solution stored at 4°C. For tryptic digestion, the 
papain pool was concentrated 5-fold in a centriprep and 1% (w/w) of 
trypsin was added. After 24 h at 4”C, the digestion was terminated by 
the addition of 0.1 mM PMSF. The reaction mixture was stored at 
4°C. 
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Fig. 1. Sedimentation analysis of the interaction of proteolytic fragments (A, papain; B, papain and trypsin) of porcine estradiol receptor with MAB 
13H2. (A) Centrifugation of estradiol receptor fragment released from heparin-Sepharose by papain (papain pool). Density gradients: 200 ~1 of 
l papain digest with -30 ng of 26 kDa receptor fragment; A, as before but incubated for 4 h at 4°C with 5 pg of MAB 13H2 IgG, layered on 
top of the gradient. (B) Density gradient analysis of tryptic estradiol receptor fragment (tryptic digest of the papain pool, Fig. 1A). 200 ~1 of l 
tryptic digest with -30 ng of 17 kDa receptor fragment; A, as before but incubated for 4 h at 4°C with 5 pg of MAB 13H2 IgG,. 
2.3. Density gradient centrifugations 
Samples of 0.2 ml, treated with dextran-coated charcoal (DCC) [17], 
were layered on 3.7 ml of linear 520% (w/v) sucrose gradients (con- 
taining 0.3 M KCl, 0.1 M sodium phosphate, pH 7.5) in SW 60 
polyallomer tubes and spun at 257,000 x g for 15 h at 2°C. Fraction- 
ation was done by upward constant-volume displacements of 0.15 ml 
each into PE counting vials. Radioactivity was measured inp-counters 
with ‘H efficiency of 50-55%. Incubations with antibodies were per- 
formed as specified in the legends of the figures. 
2.4. SDS-PAGE and Western blotting 
SDS-PAGE was performed in 1.5 mm slab gels as described [18] 
using 4% acrylamide in the stacking and 16% in the separating els. 
Samples were denatured according to [18] and run for 15 h at 60 V, 
55 mA, at 8“C. The procedure for Western blotting and immunostain- 
ing with immunoglobulin-peroxidase conjugates have been described 
previously [10,12]. 
2.5. Analyses of amino acid sequence 
Proteins were blotted on ProBlott membranes, stained with 
Coomassie R250 and the bands of interest excised with a scalpel. 
Pieces of - 2 x 4 mm were placed on top of a glas fiber filter and 
sequenced with an Applied Biosystems 477All20A microsequenator 
using standard cycles and gradients. 
3. RESULTS 
3.1. Partial puriJcation and characterisation of a 26 
kDa estradiol binding receptor fragment 
Our procedure for the isolation of estradiol binding 
receptor fragments starts with the adsorption of some 
50 nmole of ligand-filled receptor from approx. 20 1 of 
cytosol to heparin-Sepharose. After the washing steps 
(during which 8-10 nmol of receptor are shed), the sub- 
sequent recovery of the 32 kDa fragment amounts to 
25-30 nmol [lo], leaving 5-10 nmol of receptor at the 
adsorbent. We exposed this tightly bound receptor to a 
recirculated solution of different endopeptidases (tryp- 
sin, chymotrypsin and papain). Papain digestion was 
most effective and released all the remaining receptor 
while preserving the steroid attachment. The receptor 
fragment released by papain has a spec. act. of 230 nmol 
receptor/g protein with an enrichment from cytosol of 
w 770-fold. The steroid-protein complex sedimented as 
a single peak in 5-208 sucrose gradients (Fig. 1A) with- 
out dissociating during centrifugation. The monoclonal 
antibody (MAB) 13H2 binds to the estradiol-labelled 
material and gives rise to a faster sedimenting peak. The 
receptor fragment obtained by papain digestion mi- 
grates as a single 26 kDa peptide in SDS-PAGE which 
reacts both with MAB 13H2 and the polyclonal anti- 
bodies #I402 in Western immunoblots (Fig. 2). The 
mouse MAB Fl raised against estradiol dehydrogenase 
[19] was used as a control for non-specific attachment 
(lane 3). 
3.2. Preparation of a 17 kDa estradiol binding receptor 
fragment 
The 32 kDa receptor fragment [lo] and the 26 kDa 
peptide generated by papain were cleaved by 1% (w/w) 
93 





Fig. 2. Association of MAB 13H2 with denatured 26 kDa receptor 
fragment in papain digest. SDS-PAGE/Western blot of aliquots of 
papain digest containing -15 ng of 26 kDa fragment. Lane 1 stained 
with colloidal gold [25]; lane 2 stained with 13H2 IgG,-peroxidase 
conjugate; lane 3 exposed to IgG,-peroxidase conjugate of MAB Fl 
directed against estradiol 178 dehydrogenase [19]; lane 4 stained with 
Fab-S-peroxidase of #402 [lo]. Molecular masses of standards (Bio- 
Rad) are indicated. 
of trypsin for 24 h at 4°C. The specific attachment of 
estradiol is preserved during the digestion. The former 
gives rise to 3 prominent immunoreactive fragments 
(identified with MAB 13H2) with MW’s of 25, 23 and 
17 kDa (not shown). An assignment of the steroid bind- 
ing pocket to either of them is not possible. In contrast, 
Fig. 3 shows that the tryptic digestion of the 26 kDa 
peptide gives rise to a single, immunoreactive peptide of 
17 kDa. Its sedimentation velocity is a little slower than 
that of the papain fragment (Fig. 1B). Again a faster 
sedimenting complex is seen after incubating the 17 kDa 
tryptic fragment with MAB 13H2. The 17 kDa frag- 
ment, identified by MAB 13H2 in the native and in the 
SDS-denatured state, must therefore contain the steroid 
binding pocket. 
3.3. N-Terminal sequence of the tryptic 17 kDa peptide 
and alignment to sequences ofdomain E known from 
other species 
The N-terminus of the 26 kDa peptide in the papain 
digest is blocked, which occurs probably during the 
precipitation by (NH&S04. Trypsin removes the 
blocked N-terminus. and the 17 kDa peptide produced 
can be sequenced from the blot for a length of 2 I amino 
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acids. A comparison with sequences from the beginning 
of domain E of human, rat, mouse, chicken and Xen- 
opus estradiol receptor (Fig. 4) indicates a high degree 
of similarity. The only remarkable exchange is that of 
a proline in the porcine for a leucine in the human 
sequence. The N-terminal lysine of the porcine peptide 
is preceded by another lysine in the human sequence. 
The upstream cut of the 26 kDa papain peptide by 
trypsin is either at the carboxyl of this lysine or of an 
arginine. The 17 kDa mass of the tryptic peptide meas- 
ured by SDS-PAGE fits best with a downstream exten- 
sion to Lys 449 of the human sequence for a calculated 
mass of 16766 Da, which is a little more than half of the 
mass of region E. 
4. DISCUSSION 
The isolation of estradiol-filled receptor and receptor 
fragments from extracts of target tissues saturated with 
the hormone complicates the determination of their li- 
gand binding affinities by, e.g. Scatchard plot analysis. 
This apparent disadvantage is compensated for by the 
ligand-induced conformational arrest, which offers the 
chance for retrieving the native binding site from recep- 
tor digests. Its preservation in the papain 26 kDa and 
the subsequently obtained tryptic 17 kDa fragment can 





Fig. 3. Association of MAB 13H2 with denatured 17 kDa estradiol 
receptor fragment in tryptic digest. SDS-PAGE/Western blot of ali- 
quots of tryptic digest of papain pool containing - 15 ng of 17 kDa 
fragment. Goldstaining/immunostaining as in Fig. 2. 
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Fig. 4. Comparison of the N-terminal 21 amino acid sequence of the 17 kDa tryptic receptor fragment with the starts of domain E in receptors 
of other species. Starting positions of proposed domain E [I] of human (hER) [26] aligned to rat (rER) [30], mouse (mER) [29], chicken (cER) [28] 
and frog (fER) [27] sequences. 
ecular-bound estradiol in the density gradients of char- 
coal-treated solutions, (ii) their shifts to higher velocities 
after association with the monoclonal antibody 13H2, 
and (iii) the identification on the SDS-PAGE/im- 
munoblots with the same antibody. The N-terminal se- 
quence of the tryptic peptide, corresponding to the be- 
ginning of domain E, localises the estradiol binding site 
in the N-terminal part of domain E. 
Recently, CY?~’ (which should not be included in the 
17 kDa fragment) was identified as the covalent attach- 
ment site of the affinity-labeling ligands, Tamoxifen 
aziridine (Tam-AZ) and Ketononestrol aziridine [20]. 
The importance of this particular Cys, however, has 
recently been attenuated. Neither one of the mutants 
C530A and C53OS of the MCF, receptor showed a 
lesser affinity for estradiol binding and for (presumably 
Cys specific) covalent attachment of both affinity-label- 
ing compounds [6]. This also raises the question of how 
previous studies on the proteolysis of the receptor, 
which used covalently attached Tam-AZ for the identifi- 
cation of fragments [21,22], can be interpreted. At least 
one cysteinyl side chain of the estradiol receptor is indis- 
pensable for estradiol binding [23]. This must be one of 
the 3 half cystines 381, 417 and 447, of the human 
sequence (out of 4 in domain E) which are preserved in 
the 17 kDa tryptic pig receptor fragment described here 
(unpublished observation). 
The assignment of the binding site for estradiol to the 
upstream half of domain E apparently also disagrees 
with data obtained by Fawell et al. [2] from a panel of 
point mutations in the downstream half of domain E 
(amino acids 507-537) of the mouse estradiol receptor. 
This group reported major impairments of steroid bind- 
ing ability, dimerisation and DNA binding. The 
Katzenellenbogen group [24] synthesized a 42-amino 
acid peptide encompassing amino acids 510-55 1 of the 
MCF, receptor, which, however, bound neither estra- 
diol nor Tam-Az. This negative direct probing does not 
necessarily rule out the importance of amino acids 507- 
537 for high affinity estradiol binding. Some kind of 
long-range cooperativity might be responsible for the 
differing functional assignments, as concluded from the 
analysis of the estradiol-filled niche of wild-type porcine 
receptor fragments in comparison to the results of stud- 
ying the affinities for estradiol and of other functions in 
receptor mutants. 
The upstream half of domain E from Lys303 to LysM9 
of the human sequence contains 7 arginyl and 3 lysyl 
peptide bonds. All of them are conserved in the porcine 
sequence (unpublished observation) but are not suscep- 
tible to attack by trypsin under the mild cleavage condi- 
tions chosen to retain the steroid bound. The question 
of whether one linear segment of the 17 kDa peptide or 
several contribute to the niche formed for estradiol, 
therefore, remains presently unanswered. However, our 
results leave no doubt that approximately half of the 
steroid binding domain E suffices for retaining bound 
ligand. 
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